



Integrated Patient Engagement



*Case Study:
The Sanofi Patient Community
Promise and Impact on R&D*

March 2026



Integrated Patient Engagement (IPE)

Constantly evolving and improving how we engage with the patient community



Functions are illustrative not complete



Why an *Integrated Patient Engagement* model is critical for industry at this moment in time



Build trust within the patient community through transparent dialogue across the lifecycle



Support clinical trial enrolment and the pace of pipelines through forward looking partnerships that help to advance science and patient solutions



Ensure the patient community is equipped to ***generate data & deliver their perspectives*** to regulatory authorities and payers so that decisions reflect patient priorities and needs



Enable patient access through earlier alignment with the patient community on unmet need and ***preemptive identification of barriers***

How we *execute* IPE across Sanofi

The Sanofi Patient Community Promise *Unifying the entire company behind a singular purpose*

Organizational Readiness

- Upgrade structures to facilitate best in class actions
- Simplify processes for ease of collaboration
- Ensure PA teams can focus on high impact activity

Internal change

Intentional and Timely Patient Community Engagement

- Ensure strategy is informed and shaped by the patient community
- Address critical unmet needs and understand patient barriers and policy challenges
- Bring clarity regarding challenges to sustainable access to innovation

External approach

Partnership Quality Survey

- Continual monitoring of our performance
- Identification of pain points and/ or areas of new opportunities to address

Measuring results

sanofi



The Sanofi Patient Community Promise



Development of the *Sanofi Patient Community Promise*

The Promise


- Launched in **2023**, it spans the product lifestyle, with commitments grouped under four distinct sections
- Developed collaboratively with **80+ patient and caregiver organizations**
- **Endorsed by our Executive Committee**

Reporting on our commitments

The **metrics** in our Promise were included to measure how well we fulfill our commitments, and to **ensure both transparency and accountability**.

A bold approach to Patient Engagement

Sanofi is **the first pharmaceutical company to publicly report** on patient engagement metrics co-created with the patient community.



Organized *across the lifecycle* and *involving multiple functions*



LATE-STAGE RESEARCH (*clinical science units, patient informed development, health value translation, diversity in clinical trials*)

We develop medicines that reflect patient priorities.



DEVELOPMENT TO MARKET READINESS (*public affairs, legal, compliance, procurement, finance*)

We take a comprehensive approach to our partnership with the patient community.




REGULATORY AND ACCESS ACTIVITY (*regulatory, market access, public affairs, science policy*)

We advocate for people-centered health care systems.



POST LAUNCH (*medical, PV, manufacturing, public affairs*)

We improve and adapt our medicines through real-world patient community insights.



Integrated Patient Engagement in Research & Development

2025 Report

sanofi



Integrated Patient Engagement at Sanofi is driven by our Patient Community Promise, which was co-created with patients, caregivers, and patient advocacy groups around the world.

Delivering on the Patient Promise is core to what we do within Research & Development.

As part of that work, the Patient Driven Medicines Development team plays a key role in facilitating patient priorities through a Patient Disease Strategy (PDS).

Across our work, patients are building the science with us, ensuring we are focused on developing patient-centered healthcare solutions.

sanofi

We take a comprehensive approach to our partnership with the patient community

100% of clinical trials in the U.S. have Diversity & Inclusion goals to ensure our science is representative of the patient community

We advocate for people-centered health care systems

100% of global regulatory filings¹ had Patient Experience Data submitted as evidence

We develop medicines that reflect patient priorities

Patient input has been integrated in 100% of our Research & Development programs

We improve and adapt our medicines through real-world patient community insights

92% of clinical trials completed in 2025 included remote and digital solutions that make it easier for patients to participate

"Patient priorities must be the compass guiding every development milestone. When we embed their perspectives from molecule to market, we transform clinical programs into meaningful solutions that truly matter to those we serve."

Chris Corsico
Global Head, Development

In 2025:

44 drug programs were informed with patient insights – affecting 59 disease indications across 163 studies²

1. Submitted in 2024 in US, China, Japan and Europe.

2. End of Year 2025 data.

Our work is centered around the

Patient Disease Strategy

– ensuring our Research & Development is deeply patient driven.

The **Patient Disease Strategy (PDS)** is the framework grounded in patient experience data that aligns the key drivers of value defined by patients about disease treatment and healthcare landscape with all the integrated activities planned to address them.

The PDS helps ensure our medicines address patient priorities and reflect health related value to patients and their stakeholders.

Did you know?

75% of indications have a formalized PDS – but we're aiming for 100%

"Every R&D decision is a decision for a patient. When we anchor our science in what patients truly need – their priorities, their lives, their voices – we don't just develop better medicines; we fulfill our purpose."

Vicky DiBiao
Global Head, Patient Driven
Medicines Development



Each PDS includes a **patient stakeholder engagement strategy plan**



It outlines **how, with whom, and where**, we are engaging with the community – and ensures we have a proactive and comprehensive plan for partnering in a meaningful way.


sanofi



Results



Measuring our efforts through the *Partnership Quality Survey*



2025 results:



Strong *overall satisfaction*: 90% of respondents rated Sanofi as "doing well" or "doing extremely well" in listening, acting, and leading on mutual goals in support of patients



Strong *growth in scientific exchange*: 85% of respondents noted Sanofi "doing well" or "doing extremely well" providing updates to the community - compared to 74% in 2024



Significant *improvement in ease of working together*: Increased from 61% in 2024 to 91% in 2025

Increases in all *patient focused measures*



- Patient education and disease awareness improved from **83% to 90%**
- Understanding of patient experience increased from **85% to 92%**
- Identifying and addressing unmet patient needs rose from **79 to 85%**